Review: Similar safety profiles of the reference pegfilgrastim biosimilar in clinical studies
Filgrastim and pegfilgrastim are recombinant human granulocyte colony-stimulating factor (G-CSF) analogs used to prevent cancer patients from developing febrile neutropenia following chemotherapy. Pegfilgrastim biosimilars currently approved or filed for approval in the United States have demonstrated a high degree of similarity and comparability to the reference product, with no unexpected safety findings, concluded the authors …